TY - JOUR
T1 - Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
AU - Sasanelli, Myriam
AU - Meignan, Michel
AU - Haioun, Corinne
AU - Berriolo-Riedinger, Alina
AU - Casasnovas, René Olivier
AU - Biggi, Alberto
AU - Gallamini, Andrea
AU - Siegel, Barry A.
AU - Cashen, Amanda F.
AU - Véra, Pierre
AU - Tilly, Hervé
AU - Versari, Annibale
AU - Itti, Emmanuel
N1 - Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
PY - 2014/11
Y1 - 2014/11
N2 - Purpose: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).Methods: TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).Results: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p = 0.04), and prediction of OS was even better (87 % vs. 60 %, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.Conclusion: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
AB - Purpose: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).Methods: TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent 18F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41 % using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).Results: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm3. The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm3) and 60 % in the high metabolic burden group (TMTV >550 cm3, p = 0.04), and prediction of OS was even better (87 % vs. 60 %, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.Conclusion: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
KW - Diffuse large B-cell lymphoma
KW - Metabolic tumour volume
KW - Outcome prediction
KW - PET/CT
KW - Total lesion glycolysis
UR - http://www.scopus.com/inward/record.url?scp=84930973864&partnerID=8YFLogxK
U2 - 10.1007/s00259-014-2822-7
DO - 10.1007/s00259-014-2822-7
M3 - Article
C2 - 24902639
AN - SCOPUS:84930973864
SN - 1619-7070
VL - 41
SP - 2017
EP - 2022
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 11
ER -